Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients

Journal of the American Geriatrics Society

Volumn 45, Issue 6, 1997, Pages 712-717

  Fagan, Timothy C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FELODIPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0030925944     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1997.tb01475.x     Document Type: Article

References (17)

1. Elmfeldt D, Hedner J, Westerling S. Felodipine in hypertension - A review. J Cardiovasc Pharmacol 1987;10(Suppl 1):S154-160.
2. Reid JL. Dose-plasma concentration - Effect relationship of felodipine in essential hypertension: A review. J Cardiovasc Pharmacol 1990;15(Suppl.4):S50-56.
3. Landahl S, Edgar B, Cabrielsson M et al. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients, a comparison with young healthy subjects. Clin Pharmacokinet 1988;14:374-383.
4. Special Task Force Appointed by the Steering Committee, American Heart Association. Recommendations for human blood pressure determination by sphygmomanometers. Hypertension 1988;11:209-221A.
5. Iman RL. A power study of a rank transform for the two-way classification model when interaction may be present. Can J Stat 1974;2:227-239.
6. Mantel N. Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel Procedure. J Am Stat Assoc 1963;58:690-700.
7. Breslow NE, Day NE. Statistical methods in cancer research, Vol. I: The analysis of case-control studies. International Agency for Research on Cancer, Lyon, 1980.
8. Dunselman PHJM, Edgar B. Felodipine clinical pharmacokinetics. Clin Pharmacokinet 1991;21:418-430.
9. Wade JR, Sambol NC. Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. Clin Pharmacol Ther 1995;57:569-581.
10. Buhler FR, Bolli P, Kiowski et al. Renin profiling to select antihypertensive baseline drugs. Am J Med 1984;77(2A):36-42.
11. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
12. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
13. Pahor M, Guralnik JM, Corti MC et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-1197.
14. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 1995;155:2150-2156.
15. Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in hypertension? The con side. Arch Intern Med 1995;155:2157-2161.
16. Ruzicka M, Leenen FH. Reference of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, Management, 2nd Ed. New York:Raven Press, 1995, pp 2815-2825.
17. Conti CR. Use of calcium antagonists to treat heart failure. Clin Cardiol 1994;17:101-102.